Author: Chantal Bathe

Qualisure Diagnostics is pleased to announce the launch of our first diagnostic test, Thyroid GuidePx® for papillary thyroid cancer, the most common type of thyroid cancer. Thyroid GuidePx® is the…

Qualisure has submitted an international PCT patent application for the molecular subclassification of papillary thyroid cancer which is ending review. The Patent Cooperation treaty (PCT) is an international treaty with…

Qualisure was awarded a $100,000 voucher from Alberta Innovates to support further development of lead product Thyroid GuidePx™. The voucher will be applied to performing final validation tests of the…

Following an extensive evaluation of Qualisure Diagnostics; technology and commercialization plan, the University of Calgary invested in Qualisure Diagnostics Inc. through the UCeed program. The investment will be instrumental in…

The University of Calgary Department of Oncology and the Arnie Charbonneau Cancer Institute awarded $18,750 to Dr. Bathe and colleagues in endocrine surgery and pathology. The seed grant will be…

Qualisure Diagnostics Inc. and Protean BioDiagnostics Inc. together will perform the technical validation essential to launch Thyroid GuidePx™ as a Laboratory Developed Test in the United States. Protean BioDiagnostics is…

Qualisure Diagnostics Inc. and OncoHelix Inc. will collaborate to prepare Thyroid GuidePx™ for introduction to the clinic. OncoHelix’s expertise in next generation sequencing (NGS) and Precision Oncology will be leveraged…

Qualisure was awarded a $295,000 Alberta Innovates AICE-Validate grant to support further development of Thyroid GuidePx™, the next phase of the Molecular deCodeR build, and market access work. The AICE-Validate…